NCT03436797View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

November 21, 2018

Study Completion Date

April 6, 2020

Conditions
Chronic Urticaria
Interventions
DRUG

AK002

AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).

Trial Locations (4)

10117

Allakos Investigational Site, Berlin

32132

Allakos Investigational Site, Edgewater

45231

Allakos Investigational Site, Cincinnati

55131

Allakos Investigational Site, Mainz

Sponsors

Lead Sponsor

Allakos Inc.
All Listed Sponsors
lead

Allakos Inc.

INDUSTRY

NCT03436797 - A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria | Biotech Hunter | Biotech Hunter